965 related articles for article (PubMed ID: 14692652)
1. Patients with recurrent breast cancer: does the primary axillary lymph node status predict more aggressive tumor progression?
Rack B; Janni W; Gerber B; Strobl B; Schindlbeck C; Klanner E; Rammel G; Sommer H; Dimpfl T; Friese K
Breast Cancer Res Treat; 2003 Nov; 82(2):83-92. PubMed ID: 14692652
[TBL] [Abstract][Full Text] [Related]
2. Intra-mammary tumor location does not influence prognosis but influences the prevalence of axillary lymph-node metastases.
Janni W; Rack B; Sommer H; Schmidt M; Strobl B; Rjosk D; Klanner E; Thieleke W; Gerber B; Friese K; Dimpfl T
J Cancer Res Clin Oncol; 2003 Sep; 129(9):503-10. PubMed ID: 12884027
[TBL] [Abstract][Full Text] [Related]
3. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
4. Management and outcomes of isolated axillary node recurrence in breast cancer.
Konkin DE; Tyldesley S; Kennecke H; Speers CH; Olivotto IA; Davis N
Arch Surg; 2006 Sep; 141(9):867-72; discussion 872-4. PubMed ID: 16983030
[TBL] [Abstract][Full Text] [Related]
5. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
[TBL] [Abstract][Full Text] [Related]
6. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
[TBL] [Abstract][Full Text] [Related]
8. Percent positive axillary lymph node metastasis predicts survival in patients with non-metastatic breast cancer.
Lale Atahan I; Yildiz F; Ozyigit G; Sari S; Gurkaynak M; Selek U; Hayran M
Acta Oncol; 2008; 47(2):232-8. PubMed ID: 17924207
[TBL] [Abstract][Full Text] [Related]
9. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
[TBL] [Abstract][Full Text] [Related]
10. Impact of omission of axillary lymph node dissection after negative sentinel lymph node biopsy: 70-month follow-up.
Kim HJ; Son BH; Lim WS; Seo JY; Koh BS; Lee JW; Gong GY; Ahn SH
Ann Surg Oncol; 2010 Aug; 17(8):2126-31. PubMed ID: 20162458
[TBL] [Abstract][Full Text] [Related]
11. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
[TBL] [Abstract][Full Text] [Related]
12. Ratio between positive lymph nodes and total excised axillary lymph nodes as an independent prognostic factor for overall survival in patients with nonmetastatic lymph node-positive breast cancer.
Hatoum HA; Jamali FR; El-Saghir NS; Musallam KM; Seoud M; Dimassi H; Abbas J; Khalife M; Boulos FI; Tawil AN; Geara FB; Salem Z; Shamseddine AA; Al-Feghali K; Shamseddine AI
Ann Surg Oncol; 2009 Dec; 16(12):3388-95. PubMed ID: 19655200
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of residual breast disease and axillary node involvement for patients who had primary induction chemotherapy for advanced breast cancer.
Escobar PF; Patrick RJ; Rybicki LA; Hicks D; Weng DE; Crowe JP
Ann Surg Oncol; 2006 Jun; 13(6):783-7. PubMed ID: 16604475
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer.
Loya A; Guray M; Hennessy BT; Middleton LP; Buchholz TA; Valero V; Sahin AA
Cancer; 2009 Apr; 115(8):1605-12. PubMed ID: 19197997
[TBL] [Abstract][Full Text] [Related]
15. Regional nodal recurrence in the management of breast cancer patients with one to three positive axillary lymph nodes. Outcome of patients following tangential irradiation without a separate nodal field.
Stranzl H; Peintinger F; Ofner P; Prettenhofer U; Mayer R; Hackl A
Strahlenther Onkol; 2004 Oct; 180(10):623-8. PubMed ID: 15480510
[TBL] [Abstract][Full Text] [Related]
16. Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence.
Shen J; Hunt KK; Mirza NQ; Buchholz TA; Babiera GV; Kuerer HM; Bedrosian I; Ross MI; Ames FC; Feig BW; Singletary SE; Cristofanilli M; Meric-Bernstam F
Cancer; 2005 Aug; 104(3):479-90. PubMed ID: 15968686
[TBL] [Abstract][Full Text] [Related]
17. Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.
Truong PT; Olivotto IA; Kader HA; Panades M; Speers CH; Berthelet E
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1337-47. PubMed ID: 15817335
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of pathological response of primary tumor and metastatic axillary lymph nodes after neoadjuvant chemotherapy for locally advanced breast carcinoma.
Machiavelli MR; Romero AO; Pérez JE; Lacava JA; Domínguez ME; Rodríguez R; Barbieri MR; Romero Acuña LA; Romero Acuña JM; Langhi MJ; Amato S; Ortiz EH; Vallejo CT; Leone BA
Cancer J Sci Am; 1998; 4(2):125-31. PubMed ID: 9554929
[TBL] [Abstract][Full Text] [Related]
19. [Management of the axilla in breast cancer: evidences and unresolved issues].
Fodor J; Polgár C; Péley G; Németh G
Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
[TBL] [Abstract][Full Text] [Related]
20. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement.
Barranger E; Coutant C; Flahault A; Delpech Y; Darai E; Uzan S
Breast Cancer Res Treat; 2005 May; 91(2):113-9. PubMed ID: 15868438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
